CA-NEXON-AMERICA
Last week, free-to-play mobile MMORPG MapleStory M from Nexon, brought the heavens down to Maple World with the release of its first original character, Sia Astelle. This brand-new Star Guardian (Magician class) has never been seen in other global versions of MapleStory, nor has the character been available in other versions of MapleStory M before!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005080/en/
Nexon America proudly introduces Sia Astelle, the first brand new, original character in MapleStory M. (Graphic: Business Wire)
Sia Astelle is the guardian of Oort, the home to the celestial order of stars. Her first duty is in service to the cosmos, guiding stars along their destined path. After a series of strange events occur, Sia arrives in Maple World when she is forced to leave her tranquil life on Oort behind.
In addition to the new Star Guardian character, MapleStory M’s latest update boasts a wide array of improvements and events to start the new year right, including max EXP stat increase from 250% to 300%, improvements to MapleStory M's end game gear Necro equipment, skill presets, and more.
Also, while playing as Sia Astelle, mobile Maplers can benefit from bonus rewards and events:
- Pre-creation reward (1/11 after maintenance until 1/25) A reward for players who participated in ‘Sia Astelle Pre-Creation event’.
- Growth mission event (1/11 after maintenance until 2/12) - Rewards available for Sia after reaching a certain level and completing certain missions.
- Mega Burning Plus event (1/11 after maintenance until 2/12) - Sia will earn an additional 2 levels every time the character levels up.
- Grow with Sia Astelle event (1/11 after maintenance until 2/12) - Rewards and EXP will be granted to another selected character player when Sia levels up.
Other celebratory events help ring in the new year in Maple World:
- New Year event: “I Just Wanted to Have a Fulfilling Year, but Being Hero Is Too Much!” (1/11 until 2/22) - A series of multiple mini-game events where players need to save the world by participating in various tasks such as delivering food, collecting coins while hunting, and climbing trees to avoid obstacles. Maplers can also take down Lord Pixrog in a boss battle and receive rewards based on the participation count.
- 2023 Happy New Year! event (1/18 until 2/1) - Players can open lucky red envelopes with 2023 Special Energy acquired through hunting.
- 2023 Lunar New Year 14-day Login event (1/18 until 2/8) - Players can log into MapleStory M for 14 consecutive days to earn rewards!
Visit the world of MapleStory M and experience the cosmic wonder of Sia Astelle! To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Image
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines, and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and celebrates its four-year anniversary in 2022 having 16 million total downloads globally.
About Nexon America Inc. https://www.nexon.com/
Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005080/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom